Compare · LMAT vs MDLN
LMAT vs MDLN
Side-by-side comparison of LeMaitre Vascular Inc. (LMAT) and Medline Inc. (MDLN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both LMAT and MDLN operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- MDLN is the larger of the two at $45.60B, about 22.5x LMAT ($2.02B).
- MDLN has been more active in the news (18 items in the past 4 weeks vs 10 for LMAT).
- MDLN has more recent analyst coverage (25 ratings vs 16 for LMAT).
- Company
- LeMaitre Vascular Inc.
- Medline Inc.
- Price
- -
- -
- Market cap
- $2.02B
- $45.60B
- 1M return
- -
- -4.30%
- 1Y return
- -
- -14.90%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2006
- 2025
- News (4w)
- 10
- 18
- Recent ratings
- 16
- 25
LeMaitre Vascular Inc.
LeMaitre Vascular, Inc. designs, markets, sells, services, and supports medical devices and implants for the treatment of peripheral vascular disease worldwide. It offers angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries or veins; occlusion catheters that temporarily occlude the blood flow; perfusion catheters to perfuse the blood and other fluids into the vasculature; and thrombectomy catheters, which features a silicone balloon for removing thrombi in the venous system. The company also provides carotid shunts that temporarily shunt the blood to the brain during the removal of plaque from the carotid artery in a carotid endarterectomy surgery; powered phlebectomy devices to remove varicose veins; and radiopaque tape, a medical-grade tape applied to the skin that enables interventionists to cross-refer between the inside and the outside of a patient's body, and allows them to locate tributaries or lesions beneath the skin. In addition, it offers remote endarterectomy devices to remove plaque from arteries in the leg; valvulotomes, which cut valves in the saphenous vein to function as an artery to carry blood past diseased arteries to the lower leg or the foot; and vascular grafts to bypass or replace diseased arteries. Further, the company provides vascular patches, which are used for closure of vessels after surgical intervention; closure systems to attach vessels to one another with titanium clips instead of sutures; and surgical glue. It markets its products through a direct sales force and distributors. The company was formerly known as Vascutech, Inc. and changed its name to LeMaitre Vascular, Inc. in April 2001. LeMaitre Vascular, Inc. was incorporated in 1983 and is headquartered in Burlington, Massachusetts.
Latest LMAT
- SEC Form 4 filed by Director Jasinski Lawrence J
- SEC Form 4 filed by Director O'Connor John James
- SEC Form 4 filed by Director Roush John A
- SEC Form 4 filed by Director Shadan Martha
- SEC Form 4 filed by Director Pellegrino Joseph P Jr
- SEC Form 4 filed by Chief Financial Officer Leblanc Dorian Paul
- SEC Form 4 filed by President and Director Roberts David B
- SEC Form 4 filed by Senior V. P., Operations Kamke Trent G
- Chairman and CEO Lemaitre George W gifted 11,974 shares and was granted 11,974 shares, decreasing direct ownership by 0.84% to 1,418,045 units (SEC Form 4)
- LeMaitre Vascular Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
Latest MDLN
- Officer Abrams William J covered exercise/tax liability with 1,308 shares, decreasing direct ownership by 7% to 16,546 units (SEC Form 4)
- Chief Human Resources Officer Shryock Christopher P covered exercise/tax liability with 872 shares, decreasing direct ownership by 7% to 11,031 units (SEC Form 4)
- Chief Operating Officer Miller Stephen L covered exercise/tax liability with 1,889 shares, decreasing direct ownership by 7% to 23,899 units (SEC Form 4)
- Chief Legal Officer Liberman Alexander M. covered exercise/tax liability with 872 shares, decreasing direct ownership by 7% to 11,031 units (SEC Form 4)
- Chief Product Officer Laabs Amanda H. covered exercise/tax liability with 1,889 shares, decreasing direct ownership by 7% to 23,899 units (SEC Form 4)
- Chief Financial Officer Drazin Michael B covered exercise/tax liability with 1,889 shares, decreasing direct ownership by 7% to 23,899 units (SEC Form 4)
- Chief Commercial Officer Golwas Douglas P covered exercise/tax liability with 1,889 shares, converted options into 100,000 shares, sold $3,677,115 worth of shares (100,000 units at $36.77) as part of a pre-agreed trading plan and returned 100,000 units of Class B Common Stock to the company, increasing direct ownership by 1,319% to 365,864 units (SEC Form 4)
- Chief Executive Officer Boyle James M covered exercise/tax liability with 2,370 shares, decreasing direct ownership by 7% to 29,369 units (SEC Form 4)
- Director Galanti Richard A was granted 16,392 shares (SEC Form 4)
- Director Sweet Thomas W was granted 17,800 shares (SEC Form 4)